Opinion|Videos|September 30, 2024
Educational Initiatives to Enhance Guideline Adherence in CRM
Key Takeaways
- Targeted education, including workshops and webinars, can enhance provider awareness of evidence-based guidelines for CRM conditions.
- Emphasizing the importance of annual uACR and eGFR testing can improve CKD screening and early detection.
Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What educational initiatives can be implemented to improve healthcare provider awareness and adherence to evidence-based guidelines in patients with CRM conditions?
- For example, how could targeted education improve annual testing for uACR and eGFR to screen for CKD?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
5 Things to Know About the One Big Beautiful Bill Act
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5